DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $92,767 | -10.3% | 401 | -3.8% | 0.03% | -15.2% |
| Q3 2023 | $103,458 | +8.9% | 417 | +5.3% | 0.03% | +10.0% |
| Q2 2023 | $95,040 | -38.1% | 396 | -35.0% | 0.03% | -42.3% |
| Q1 2023 | $153,443 | +93.3% | 609 | +103.7% | 0.05% | +79.3% |
| Q4 2022 | $79,361 | +3.1% | 299 | 0.0% | 0.03% | -3.3% |
| Q3 2022 | $77,000 | +1.3% | 299 | 0.0% | 0.03% | +7.1% |
| Q2 2022 | $76,000 | -13.6% | 299 | 0.0% | 0.03% | 0.0% |
| Q1 2022 | $88,000 | -12.0% | 299 | -1.3% | 0.03% | -15.2% |
| Q4 2021 | $100,000 | +8.7% | 303 | 0.0% | 0.03% | 0.0% |
| Q3 2021 | $92,000 | +8.2% | 303 | -4.1% | 0.03% | +6.5% |
| Q2 2021 | $85,000 | +19.7% | 316 | -0.3% | 0.03% | +19.2% |
| Q1 2021 | $71,000 | +1.4% | 317 | 0.0% | 0.03% | -7.1% |
| Q4 2020 | $70,000 | +2.9% | 317 | -0.6% | 0.03% | -6.7% |
| Q3 2020 | $68,000 | +21.4% | 319 | 0.0% | 0.03% | +15.4% |
| Q2 2020 | $56,000 | +27.3% | 319 | -0.6% | 0.03% | +13.0% |
| Q1 2020 | $44,000 | 0.0% | 321 | +10.3% | 0.02% | +4.5% |
| Q4 2019 | $44,000 | 0.0% | 291 | -5.2% | 0.02% | +4.8% |
| Q3 2019 | $44,000 | -6.4% | 307 | -8.4% | 0.02% | 0.0% |
| Q2 2019 | $47,000 | -62.1% | 335 | -37.3% | 0.02% | -19.2% |
| Q1 2019 | $124,000 | +138.5% | 534 | +4.9% | 0.03% | +8.3% |
| Q4 2018 | $52,000 | -5.5% | 509 | 0.0% | 0.02% | +9.1% |
| Q3 2018 | $55,000 | +10.0% | 509 | 0.0% | 0.02% | +4.8% |
| Q2 2018 | $50,000 | +2.0% | 509 | 0.0% | 0.02% | +5.0% |
| Q1 2018 | $49,000 | +4.3% | 509 | 0.0% | 0.02% | +5.3% |
| Q4 2017 | $47,000 | +9.3% | 509 | 0.0% | 0.02% | -17.4% |
| Q3 2017 | $43,000 | +2.4% | 509 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $42,000 | -2.3% | 509 | 0.0% | 0.02% | -4.2% |
| Q1 2017 | $43,000 | +10.3% | 509 | 0.0% | 0.02% | +9.1% |
| Q4 2016 | $39,000 | -7.1% | 509 | -6.4% | 0.02% | -8.3% |
| Q3 2016 | $42,000 | -23.6% | 544 | -1.8% | 0.02% | -25.0% |
| Q2 2016 | $55,000 | +5.8% | 554 | 0.0% | 0.03% | +3.2% |
| Q1 2016 | $52,000 | +6.1% | 554 | +3.9% | 0.03% | 0.0% |
| Q4 2015 | $49,000 | – | 533 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |